Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-Check: Durvalumab + Tremelimumab in 2nd-line NSCLC
NCT05383001Phase 2Withdrawn
- Sponsor
- AIO-Studien
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tremelimumab and durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-Free Survival 1 at 49 months. Planned start May 2022; status: withdrawn.
02
Drugs
tremelimumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05383001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383001.